search
Back to results

Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease (SensiCare)

Primary Purpose

Alzheimer Disease

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Multi-sensory supportive care
Sponsored by
Centre Hospitalier Universitaire de Nīmes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Alzheimer Disease focused on measuring Snoezelen, Multi-sensorial care session, Alzheimer's-type neurodegenerative disease, Dementia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patient's legal representative must have given his/her informed and signed consent (or the patient if he/she is judged competent)
  • The patient must be insured or beneficiary of a health insurance plan
  • Alzheimer's-type neurodegenerative pathology
  • The patient has been living in the participating center for > 2 months

Exclusion Criteria:

  • The patient's legal representative refuses to sign the consent (or the patient if he/she is judged competent)
  • It is impossible to correctly inform the patient's legal representative
  • The patient has already has Snoezelen-therapy

Sites / Locations

  • CHU de Nîmes - Centre de Gérontologie de Serre Cavalier

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Study population

Arm Description

Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).

Outcomes

Primary Outcome Measures

Change from baseline in NPI-Q scores

Secondary Outcome Measures

Change from baseline in NPI-Q scores
Change from baseline in NPI-Q scores
Change from baseline in NPI-Q scores
Change from baseline in the Quality-of-life-Alzheimer's Disease questionnaire (QOL-AD)
Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire
Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire
Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire
Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire
Change in drug consumption from baseline
Change in drug consumption from baseline
Change in drug consumption from baseline
Change in drug consumption from baseline

Full Information

First Posted
March 25, 2013
Last Updated
April 28, 2015
Sponsor
Centre Hospitalier Universitaire de Nīmes
search

1. Study Identification

Unique Protocol Identification Number
NCT01819714
Brief Title
Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease
Acronym
SensiCare
Official Title
Evaluation of the Impact of Care Based on Sensory Support for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
June 2013 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nīmes

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of this study is to evaluate the effect of 3 months of "Snoezelen-type" multi-sensory care sessions on NeuroPsychiatric Inventory Questionnaire (NPI-Q) scores for patients with Alzheimer's-type neurodegenerative disease.
Detailed Description
The secondary objectives of this study are to study the following elements in relationship to the implementation of a "Snoezelen-type" multi-sensory care strategy for patients with Alzheimer's-type neurodegenerative disease: A. to evaluate the effects on NPI-Q scores at 1 month, 6 months and 12 months . B. evaluate the effects on quality of life (questionnaire QOL-AD) at 0 and 12 months. C. assess changes in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire over 0, 1, 3, 6 and 12 months. D. assess changes in drug consumption (anxiolytics, antidepressants, hypnotics, neuroleptics)over the study period

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
Snoezelen, Multi-sensorial care session, Alzheimer's-type neurodegenerative disease, Dementia

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Study population
Arm Type
Experimental
Arm Description
Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
Intervention Type
Other
Intervention Name(s)
Multi-sensory supportive care
Other Intervention Name(s)
Snoezelen-type care, Snoezelen toilette
Intervention Description
The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care. The impact of this multisensory strategy will be evaluated using a before-after design.
Primary Outcome Measure Information:
Title
Change from baseline in NPI-Q scores
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Change from baseline in NPI-Q scores
Time Frame
1 month
Title
Change from baseline in NPI-Q scores
Time Frame
6 months
Title
Change from baseline in NPI-Q scores
Time Frame
12 months
Title
Change from baseline in the Quality-of-life-Alzheimer's Disease questionnaire (QOL-AD)
Time Frame
12 months
Title
Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire
Time Frame
1 month
Title
Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire
Time Frame
3 months
Title
Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire
Time Frame
6 months
Title
Change from baseline in the "aggressive behavior" subsection of the Cohen-Mansfield Agitation Inventory (CMAI) questionnaire
Time Frame
12 months
Title
Change in drug consumption from baseline
Time Frame
1 month
Title
Change in drug consumption from baseline
Time Frame
3 months
Title
Change in drug consumption from baseline
Time Frame
6 months
Title
Change in drug consumption from baseline
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient's legal representative must have given his/her informed and signed consent (or the patient if he/she is judged competent) The patient must be insured or beneficiary of a health insurance plan Alzheimer's-type neurodegenerative pathology The patient has been living in the participating center for > 2 months Exclusion Criteria: The patient's legal representative refuses to sign the consent (or the patient if he/she is judged competent) It is impossible to correctly inform the patient's legal representative The patient has already has Snoezelen-therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jane Debuysschere, IDE
Organizational Affiliation
Centre Hospitalier Universitaire de Nîmes
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jean-Marie Cros, MD
Organizational Affiliation
Centre Hospitalier Universitaire de Nîmes
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Nîmes - Centre de Gérontologie de Serre Cavalier
City
Nîmes
ZIP/Postal Code
30029
Country
France

12. IPD Sharing Statement

Learn more about this trial

Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease

We'll reach out to this number within 24 hrs